首页 > 最新文献

BJU International最新文献

英文 中文
Prophylactic urethrectomy at the time of radical cystectomy for bladder cancer: does it really have an effect on oncological outcomes? 膀胱癌根治性膀胱切除术时预防性尿道切除术:它真的对肿瘤预后有影响吗?
IF 4.5 2区 医学 Q1 UROLOGY & NEPHROLOGY Pub Date : 2025-12-23 DOI: 10.1111/bju.70096
Jonas Mennes,Murat Akand,Rodrigue Benijts,Loïc Baekelandt,Wouter Everaerts,Maarten Albersen,Hendrik Van Poppel,Frank Van der Aa,Steven Joniau
OBJECTIVETo assess the oncological impact of prophylactic urethrectomy (PU) on recurrence, metastasis, and survival outcomes, as PU was historically performed alongside radical cystectomy (RC) in men but has become rare with the increasing use of orthotopic neobladder substitution and uncertain survival benefits.PATIENTS AND METHODSA total of 1028 patients underwent RC at a single tertiary referral center between 1996 and 2022. Among them, 581 males who received either incontinent urinary diversion or continent cutaneous diversion were identified. A propensity score matching was performed to minimise selection bias, yielding a cohort of 332 patients, of whom 166 underwent PU and 166 did not. Kaplan-Meier survival analysis was conducted to evaluate recurrence-free survival (RFS), urethral recurrence-free survival (URFS), cancer-specific survival (CSS), and overall survival (OS) at multiple time points postoperatively. Differences in survival outcomes between the two groups were assessed using the log-rank test.RESULTSA trend toward improved CSS was observed in the PU group; however, the difference was not significant, and no notable variation was found in RFS. At 10 years, URFS was higher in the PU group (97.9% vs 90.9%, P = 0.05), but after matching, this difference (98.2% vs 95.9%) was no longer significant. A significant improvement in OS was observed among patients who underwent PU, with a 10-year survival rate of 47.3% compared to 27.5% in those who did not receive the procedure (P = 0.002). Independent predictors of OS included age ≥80 years (P = 0.013), Charlson Comorbidity Index score ≥3 (P = 0.002), pathological N-stage ≥N1 (P < 0.001), positive surgical margins (P < 0.001), and performing PU (P = 0.015).CONCLUSIONSPatients undergoing PU had significantly improved OS at 2-, 5-, and 10-year follow-up compared to those who did not. No significant differences were found in CSS and RFS. While PU was associated with a reduced risk of urethral recurrence at 10 years, this advantage was no longer significant after adjusting for confounders. The procedure may be most beneficial for select patients, particularly those with prostatic urethral involvement.
目的评估预防性尿道切除术(PU)对复发、转移和生存结果的肿瘤学影响,因为PU历来与根治性膀胱切除术(RC)一起在男性中进行,但随着原位新膀胱替代术的使用越来越多,且生存效益不确定,PU已变得罕见。患者和方法1996年至2022年间,共有1028名患者在单一三级转诊中心接受了RC。其中581例男性行尿失禁改道或皮肤改道。为了尽量减少选择偏差,进行了倾向评分匹配,产生了332例患者,其中166例接受了PU, 166例未接受PU。采用Kaplan-Meier生存分析评估术后多个时间点的无复发生存(RFS)、尿道无复发生存(URFS)、癌症特异性生存(CSS)和总生存(OS)。使用log-rank检验评估两组间生存结果的差异。结果PU组有改善CSS的sa趋势;但差异不显著,RFS无显著差异。10年时,PU组的URFS较高(97.9% vs 90.9%, P = 0.05),但配对后,这一差异(98.2% vs 95.9%)不再显著。接受PU治疗的患者的OS有显著改善,10年生存率为47.3%,而未接受PU治疗的患者为27.5% (P = 0.002)。OS的独立预测因子包括年龄≥80岁(P = 0.013)、Charlson合并症指数评分≥3分(P = 0.002)、病理n分期≥N1 (P < 0.001)、手术切缘阳性(P < 0.001)和行PU (P = 0.015)。结论:与未接受PU治疗的患者相比,接受PU治疗的患者在2年、5年和10年随访时的OS显著改善。CSS和RFS无显著差异。虽然PU与10年尿道复发风险降低相关,但在调整混杂因素后,这一优势不再显著。该手术可能对特定的患者最有利,特别是那些前列腺尿道受累的患者。
{"title":"Prophylactic urethrectomy at the time of radical cystectomy for bladder cancer: does it really have an effect on oncological outcomes?","authors":"Jonas Mennes,Murat Akand,Rodrigue Benijts,Loïc Baekelandt,Wouter Everaerts,Maarten Albersen,Hendrik Van Poppel,Frank Van der Aa,Steven Joniau","doi":"10.1111/bju.70096","DOIUrl":"https://doi.org/10.1111/bju.70096","url":null,"abstract":"OBJECTIVETo assess the oncological impact of prophylactic urethrectomy (PU) on recurrence, metastasis, and survival outcomes, as PU was historically performed alongside radical cystectomy (RC) in men but has become rare with the increasing use of orthotopic neobladder substitution and uncertain survival benefits.PATIENTS AND METHODSA total of 1028 patients underwent RC at a single tertiary referral center between 1996 and 2022. Among them, 581 males who received either incontinent urinary diversion or continent cutaneous diversion were identified. A propensity score matching was performed to minimise selection bias, yielding a cohort of 332 patients, of whom 166 underwent PU and 166 did not. Kaplan-Meier survival analysis was conducted to evaluate recurrence-free survival (RFS), urethral recurrence-free survival (URFS), cancer-specific survival (CSS), and overall survival (OS) at multiple time points postoperatively. Differences in survival outcomes between the two groups were assessed using the log-rank test.RESULTSA trend toward improved CSS was observed in the PU group; however, the difference was not significant, and no notable variation was found in RFS. At 10 years, URFS was higher in the PU group (97.9% vs 90.9%, P = 0.05), but after matching, this difference (98.2% vs 95.9%) was no longer significant. A significant improvement in OS was observed among patients who underwent PU, with a 10-year survival rate of 47.3% compared to 27.5% in those who did not receive the procedure (P = 0.002). Independent predictors of OS included age ≥80 years (P = 0.013), Charlson Comorbidity Index score ≥3 (P = 0.002), pathological N-stage ≥N1 (P < 0.001), positive surgical margins (P < 0.001), and performing PU (P = 0.015).CONCLUSIONSPatients undergoing PU had significantly improved OS at 2-, 5-, and 10-year follow-up compared to those who did not. No significant differences were found in CSS and RFS. While PU was associated with a reduced risk of urethral recurrence at 10 years, this advantage was no longer significant after adjusting for confounders. The procedure may be most beneficial for select patients, particularly those with prostatic urethral involvement.","PeriodicalId":8985,"journal":{"name":"BJU International","volume":"167 1","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145807876","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Trends in treatment and survival of older vs younger patients with renal cancer between 2011 and 2022. 2011年至2022年间老年肾癌患者与年轻肾癌患者的治疗和生存趋势
IF 4.5 2区 医学 Q1 UROLOGY & NEPHROLOGY Pub Date : 2025-12-23 DOI: 10.1111/bju.70116
Hilin Yildirim,Melinda S Schuurman,Harm H E van Melick,Adriaan D Bins,Patricia J Zondervan,Katja K H Aben
{"title":"Trends in treatment and survival of older vs younger patients with renal cancer between 2011 and 2022.","authors":"Hilin Yildirim,Melinda S Schuurman,Harm H E van Melick,Adriaan D Bins,Patricia J Zondervan,Katja K H Aben","doi":"10.1111/bju.70116","DOIUrl":"https://doi.org/10.1111/bju.70116","url":null,"abstract":"","PeriodicalId":8985,"journal":{"name":"BJU International","volume":"35 1","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145807875","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Aquablation for benign prostatic hyperplasia: real‐world prostate size relevance and bleeding events across 6 years 水消融治疗良性前列腺增生:6年来真实世界前列腺大小的相关性和出血事件
IF 4.5 2区 医学 Q1 UROLOGY & NEPHROLOGY Pub Date : 2025-12-16 DOI: 10.1111/bju.70118
Mario Bitar, Roseanne Ferreira, Sagi Shprits, Omar Buksh, Naeem Bhojani, Bilal Chughtai, Kevin C. Zorn, Dean Elterman
Objective To present large‐scale safety outcomes, with a particular focus on postoperative bleeding following Aquablation for benign prostatic hyperplasia. Patients and Methods Patients who underwent Aquablation between 2019 and 2024 across Asia, Europe, and North America were assessed to evaluate trends in treated prostate sizes, which were visualised using density plots. A corporate prospective database was maintained, incorporating case recordings and data collected by on‐site company representatives. In addition, the incidence of postoperative bleeding—defined as transfusion or surgical takeback for haemostatic fulguration—was analysed using data from the United States Food and Drug Administration (FDA) Manufacturer and User Facility Device Experience (MAUDE) database and procedure counts by the manufacturer. Results A total of 70 270 Aquablation procedures were evaluated over the period from 2019 to 2024. The mean (standard deviation) prostate volume was 87.3 (42.4) mL, with a maximum recorded size of 1189 mL. Density plot analysis of prostate volumes demonstrated consistent utilisation of Aquablation across the full range of prostate sizes throughout all years studied. The overall rate of blood transfusion or return to the operating room for haemostatic fulguration was 0.2%, indicating a favourable safety profile across a very wide range of prostate sizes. Conclusions Aquablation has been consistently utilised across a broad spectrum of prostate sizes, with a low overall rate of transfusion or return to the operating room for bleeding control. These findings highlight the procedure's broad applicability and favourable safety profile in real‐world practice from 2019 to 2024.
目的:展示大规模的安全性结果,特别关注良性前列腺增生水消融术后出血。研究人员对亚洲、欧洲和北美地区2019年至2024年间接受水消融治疗的患者进行了评估,以评估治疗后前列腺大小的趋势,并使用密度图将其可视化。公司的前瞻性数据库被维护,包括案例记录和现场公司代表收集的数据。此外,使用美国食品和药物管理局(FDA)制造商和用户设施设备体验(MAUDE)数据库的数据和制造商的程序计数分析了术后出血(定义为输血或止血电光手术回收)的发生率。结果2019年至2024年共评估了70 270例水消融手术。前列腺体积的平均(标准偏差)为87.3 (42.4)mL,最大记录尺寸为1189 mL。前列腺体积的密度图分析表明,在所有研究年份中,在前列腺大小的整个范围内,Aquablation的使用是一致的。输血或返回手术室进行止血电灼的总体比率为0.2%,表明在非常大范围的前列腺尺寸范围内具有良好的安全性。结论:水溶消融术已广泛应用于前列腺大小,输血或返回手术室控制出血的总体率较低。这些发现突出了该程序在2019年至2024年的现实世界实践中的广泛适用性和良好的安全性。
{"title":"Aquablation for benign prostatic hyperplasia: real‐world prostate size relevance and bleeding events across 6 years","authors":"Mario Bitar, Roseanne Ferreira, Sagi Shprits, Omar Buksh, Naeem Bhojani, Bilal Chughtai, Kevin C. Zorn, Dean Elterman","doi":"10.1111/bju.70118","DOIUrl":"https://doi.org/10.1111/bju.70118","url":null,"abstract":"Objective To present large‐scale safety outcomes, with a particular focus on postoperative bleeding following Aquablation for benign prostatic hyperplasia. Patients and Methods Patients who underwent Aquablation between 2019 and 2024 across Asia, Europe, and North America were assessed to evaluate trends in treated prostate sizes, which were visualised using density plots. A corporate prospective database was maintained, incorporating case recordings and data collected by on‐site company representatives. In addition, the incidence of postoperative bleeding—defined as transfusion or surgical takeback for haemostatic fulguration—was analysed using data from the United States Food and Drug Administration (FDA) Manufacturer and User Facility Device Experience (MAUDE) database and procedure counts by the manufacturer. Results A total of 70 270 Aquablation procedures were evaluated over the period from 2019 to 2024. The mean (standard deviation) prostate volume was 87.3 (42.4) mL, with a maximum recorded size of 1189 mL. Density plot analysis of prostate volumes demonstrated consistent utilisation of Aquablation across the full range of prostate sizes throughout all years studied. The overall rate of blood transfusion or return to the operating room for haemostatic fulguration was 0.2%, indicating a favourable safety profile across a very wide range of prostate sizes. Conclusions Aquablation has been consistently utilised across a broad spectrum of prostate sizes, with a low overall rate of transfusion or return to the operating room for bleeding control. These findings highlight the procedure's broad applicability and favourable safety profile in real‐world practice from 2019 to 2024.","PeriodicalId":8985,"journal":{"name":"BJU International","volume":"2 1","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-12-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145759788","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Impact of BRCA in patients undergoing abiraterone ± stereotactic body radiotherapy: the ARTO trial. BRCA对接受阿比特龙±立体定向体放疗患者的影响:ARTO试验。
IF 4.5 2区 医学 Q1 UROLOGY & NEPHROLOGY Pub Date : 2025-12-15 DOI: 10.1111/bju.70070
Giulio Francolini,Vanessa Di Cataldo,Pietro Garlatti,Niccolò Bertini,Michele Aquilano,Saverio Caini,Gianluca Ingrosso,Alessio Bruni,Rolando Maria D'Angelillo,Luca Tagliaferri,Matteo Augugliaro,Luca Triggiani,Silvana Parisi,Gabriele Simontacchi,Barbara Alicja Jereczek-Fossa,Giulia Marvaso,Filippo Alongi,Fabio Arcidiacono,Andrea Lancia,Marta Scorsetti,Isacco Desideri,Icro Meattini,Monica Mangoni,Lorenzo Masieri,Lorenzo Livi,
{"title":"Impact of BRCA in patients undergoing abiraterone ± stereotactic body radiotherapy: the ARTO trial.","authors":"Giulio Francolini,Vanessa Di Cataldo,Pietro Garlatti,Niccolò Bertini,Michele Aquilano,Saverio Caini,Gianluca Ingrosso,Alessio Bruni,Rolando Maria D'Angelillo,Luca Tagliaferri,Matteo Augugliaro,Luca Triggiani,Silvana Parisi,Gabriele Simontacchi,Barbara Alicja Jereczek-Fossa,Giulia Marvaso,Filippo Alongi,Fabio Arcidiacono,Andrea Lancia,Marta Scorsetti,Isacco Desideri,Icro Meattini,Monica Mangoni,Lorenzo Masieri,Lorenzo Livi, ","doi":"10.1111/bju.70070","DOIUrl":"https://doi.org/10.1111/bju.70070","url":null,"abstract":"","PeriodicalId":8985,"journal":{"name":"BJU International","volume":"362 1","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145752615","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Response to 'Comment on robot-assisted partial nephrectomy using the Hugo™ RAS system: first multicentre study'. 对“关于使用Hugo™RAS系统的机器人辅助部分肾切除术的评论:首次多中心研究”的回应。
IF 4.5 2区 医学 Q1 UROLOGY & NEPHROLOGY Pub Date : 2025-12-14 DOI: 10.1111/bju.70099
Francesco Prata,Riccardo Bertolo,Paolo Dell'Oglio,Angelo Mottaran,Riccardo Schiavina,Antonio Galfano,Alessandro Antonelli,Rocco Papalia
{"title":"Response to 'Comment on robot-assisted partial nephrectomy using the Hugo™ RAS system: first multicentre study'.","authors":"Francesco Prata,Riccardo Bertolo,Paolo Dell'Oglio,Angelo Mottaran,Riccardo Schiavina,Antonio Galfano,Alessandro Antonelli,Rocco Papalia","doi":"10.1111/bju.70099","DOIUrl":"https://doi.org/10.1111/bju.70099","url":null,"abstract":"","PeriodicalId":8985,"journal":{"name":"BJU International","volume":"1 1","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-12-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145752743","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparable recurrence risk for MRI-detected Gleason Grade Group (GG) 2 and systematic biopsy-detected GG1 prostate cancer. mri检测Gleason分级组(GG) 2和系统活检检测GG1前列腺癌的复发风险相当。
IF 4.5 2区 医学 Q1 UROLOGY & NEPHROLOGY Pub Date : 2025-12-14 DOI: 10.1111/bju.70109
Abderrahim-Oussama Batouche,Eugen Czeizler,Timo-Pekka Lehto,Andrew Erickson,Tolou Shadbahr,Teemu D Laajala,Joona Pohjonen,Tuomas Mirtti,Antti S Rannikko
OBJECTIVETo determine the likelihood of definitive treatment and risk of post-treatment recurrence for patients with Gleason Grade Group (GG) 2 cancer diagnosed using targeted biopsies relative to men with GG1 cancer diagnosed using systematic biopsies.MATERIALS AND METHODSWe performed a retrospective study using a large tertiary centre registry (the HUS Acamedic data lake) to retrieve data on prostate cancer (PCa) diagnosis, treatment, and cancer recurrence. We included patients with either GG1 PCa detected by systematic biopsies (n = 3317) or GG2 PCa detected with targeted biopsies (n = 554) between 1993 and 2019. We assessed the risk of curative treatment and recurrence after treatment. Kaplan-Meier curves were used to estimate treatment- and recurrence-free survival, and Cox proportional hazards regression was used to evaluate the risk of post-treatment recurrence.RESULTSPatients with systematic biopsy-detected GG1 cancer had a significantly longer median time to treatment (31 months) than those with targeted biopsy-detected GG2 cancer (4 months; P < 0.0001). Risk of recurrence after curative treatment was similar in the two groups, with the upper bound of the 95% confidence interval (CI) excluding any significant difference (hazard ratio 1.04, 95% CI 0.75-1.43; P = 0.83).CONCLUSIONMen diagnosed with GG2 PCa based on MRI-targeted biopsy had a similar risk of recurrence after treatment compared to men with GG1 disease diagnosed using systematic biopsy, although they were more likely to undergo curative treatment. These findings suggest that at least a portion of the apparent increase in GG2 diagnoses in the MRI era may reflect reclassification rather than more aggressive disease. Improved risk stratification is needed to identify which men with MRI-era GG2 cancer may be suitable for active surveillance.
目的:相对于采用系统活检诊断为GG1癌的男性,采用靶向活检诊断为Gleason Grade Group (GG) 2癌的患者确定治疗的可能性和治疗后复发的风险。材料和方法我们使用一个大型三级中心登记处(HUS学术数据湖)进行了一项回顾性研究,以检索前列腺癌(PCa)的诊断、治疗和癌症复发的数据。我们纳入了1993年至2019年间通过系统活检检测到GG1型前列腺癌(n = 3317)或通过靶向活检检测到GG2型前列腺癌(n = 554)的患者。我们评估了治愈治疗和治疗后复发的风险。Kaplan-Meier曲线用于估计无治疗和无复发生存期,Cox比例风险回归用于评估治疗后复发风险。结果系统活检检测到GG1癌患者的中位治疗时间(31个月)明显长于靶向活检检测到GG2癌患者(4个月,P < 0.0001)。两组治愈后复发的风险相似,95%置信区间(CI)上界排除任何显著差异(风险比1.04,95% CI 0.75-1.43; P = 0.83)。结论与系统活检诊断为GG1的男性相比,基于mri靶向活检诊断为GG2的男性治疗后复发的风险相似,尽管他们更有可能接受根治性治疗。这些发现表明,在MRI时代GG2诊断的明显增加中,至少有一部分可能反映了重新分类,而不是更具侵袭性的疾病。需要改进风险分层,以确定哪些患有mri时代GG2癌的男性可能适合进行主动监测。
{"title":"Comparable recurrence risk for MRI-detected Gleason Grade Group (GG) 2 and systematic biopsy-detected GG1 prostate cancer.","authors":"Abderrahim-Oussama Batouche,Eugen Czeizler,Timo-Pekka Lehto,Andrew Erickson,Tolou Shadbahr,Teemu D Laajala,Joona Pohjonen,Tuomas Mirtti,Antti S Rannikko","doi":"10.1111/bju.70109","DOIUrl":"https://doi.org/10.1111/bju.70109","url":null,"abstract":"OBJECTIVETo determine the likelihood of definitive treatment and risk of post-treatment recurrence for patients with Gleason Grade Group (GG) 2 cancer diagnosed using targeted biopsies relative to men with GG1 cancer diagnosed using systematic biopsies.MATERIALS AND METHODSWe performed a retrospective study using a large tertiary centre registry (the HUS Acamedic data lake) to retrieve data on prostate cancer (PCa) diagnosis, treatment, and cancer recurrence. We included patients with either GG1 PCa detected by systematic biopsies (n = 3317) or GG2 PCa detected with targeted biopsies (n = 554) between 1993 and 2019. We assessed the risk of curative treatment and recurrence after treatment. Kaplan-Meier curves were used to estimate treatment- and recurrence-free survival, and Cox proportional hazards regression was used to evaluate the risk of post-treatment recurrence.RESULTSPatients with systematic biopsy-detected GG1 cancer had a significantly longer median time to treatment (31 months) than those with targeted biopsy-detected GG2 cancer (4 months; P < 0.0001). Risk of recurrence after curative treatment was similar in the two groups, with the upper bound of the 95% confidence interval (CI) excluding any significant difference (hazard ratio 1.04, 95% CI 0.75-1.43; P = 0.83).CONCLUSIONMen diagnosed with GG2 PCa based on MRI-targeted biopsy had a similar risk of recurrence after treatment compared to men with GG1 disease diagnosed using systematic biopsy, although they were more likely to undergo curative treatment. These findings suggest that at least a portion of the apparent increase in GG2 diagnoses in the MRI era may reflect reclassification rather than more aggressive disease. Improved risk stratification is needed to identify which men with MRI-era GG2 cancer may be suitable for active surveillance.","PeriodicalId":8985,"journal":{"name":"BJU International","volume":"14 1","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-12-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145752610","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comment on 'Male sex is a risk factor for detrusor pressure jeopardising the upper urinary tract after spinal cord injury'. 评论“男性是脊髓损伤后逼尿肌压力危及上尿路的危险因素”。
IF 4.5 2区 医学 Q1 UROLOGY & NEPHROLOGY Pub Date : 2025-12-14 DOI: 10.1111/bju.70107
Longtu Ma,Rui Lu,Zhilong Dong
{"title":"Comment on 'Male sex is a risk factor for detrusor pressure jeopardising the upper urinary tract after spinal cord injury'.","authors":"Longtu Ma,Rui Lu,Zhilong Dong","doi":"10.1111/bju.70107","DOIUrl":"https://doi.org/10.1111/bju.70107","url":null,"abstract":"","PeriodicalId":8985,"journal":{"name":"BJU International","volume":"57 1","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-12-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145752747","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Expanding the evidence base for Uromonitor®: updated pooled performance across eight cohorts. 扩展Uromonitor®的证据基础:更新八个队列的汇总性能。
IF 4.5 2区 医学 Q1 UROLOGY & NEPHROLOGY Pub Date : 2025-12-14 DOI: 10.1111/bju.70113
Matthias May,Anton Kravchuk,Ralph M Wirtz,Thorsten H Ecke,Axel Heidenreich
{"title":"Expanding the evidence base for Uromonitor®: updated pooled performance across eight cohorts.","authors":"Matthias May,Anton Kravchuk,Ralph M Wirtz,Thorsten H Ecke,Axel Heidenreich","doi":"10.1111/bju.70113","DOIUrl":"https://doi.org/10.1111/bju.70113","url":null,"abstract":"","PeriodicalId":8985,"journal":{"name":"BJU International","volume":"170 1","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-12-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145752614","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Response to: ‘Expanding the evidence base for Uromonitor®: updated pooled performance across eight cohorts’ 回应:“扩大Uromonitor®的证据基础:更新八个队列的汇总性能”
IF 4.5 2区 医学 Q1 UROLOGY & NEPHROLOGY Pub Date : 2025-12-13 DOI: 10.1111/bju.70114
José Rubio‐Briones
{"title":"Response to: ‘Expanding the evidence base for Uromonitor®: updated pooled performance across eight cohorts’","authors":"José Rubio‐Briones","doi":"10.1111/bju.70114","DOIUrl":"https://doi.org/10.1111/bju.70114","url":null,"abstract":"","PeriodicalId":8985,"journal":{"name":"BJU International","volume":"6 1","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-12-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145731055","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
RE: Comment: ‘Male sex is a risk factor for detrusor pressure jeopardising the upper urinary tract in patients with spinal cord injury’ 评论:“男性是脊髓损伤患者逼尿肌压力危及上尿路的危险因素”
IF 4.5 2区 医学 Q1 UROLOGY & NEPHROLOGY Pub Date : 2025-12-10 DOI: 10.1111/bju.70106
Collene E. Anderson, Veronika Birkhäuser, Martin W. G. Brinkhof, Thomas M. Kessler
{"title":"RE: Comment: ‘Male sex is a risk factor for detrusor pressure jeopardising the upper urinary tract in patients with spinal cord injury’","authors":"Collene E. Anderson, Veronika Birkhäuser, Martin W. G. Brinkhof, Thomas M. Kessler","doi":"10.1111/bju.70106","DOIUrl":"https://doi.org/10.1111/bju.70106","url":null,"abstract":"","PeriodicalId":8985,"journal":{"name":"BJU International","volume":"98 1","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145711403","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
BJU International
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1